Login
$LYEL
$14.65 +$0.35 (2.45%) Live

$LYEL SEC Filings

Filed On Filing
13 Nov 2026 S-3
12 Nov 2026 Form 4: Lee Gary K., Chief Scientific Officer

Sold 129 shares ($2.05K)

12 Nov 2026 Form 4: Hill Stephen J., Chief Operating Officer

Sold 88 shares ($1.4K)

12 Nov 2026 Form 4: Seely Lynn, Director

Sold 545 shares ($8.68K)

12 Nov 2026 Form 4: Bulis Veronica Sanchez, VP, Corporate Controller

Sold 416 shares ($6.63K)

10 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 Form 4: Arch Venture Partners IX, Llc, 10% owner and 4 others

Bought 2,321,262 shares ($25M)

05 Nov 2026 Form 4: Arch Venture Fund XIII, L.p., 10% owner and 8 others

Bought 2,321,262 shares ($25M)

04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., November 4, 2026 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, to...

04 Nov 2026 8-K: Unregistered Sales of Equity Securities

On November 3, 2026, Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to...

13 Oct 2026 Form 4: Aguirre Jarrad Mattieu, Chief Medical Officer

Sold 422 shares ($3.64K)

10 Sep 2026 Form 4: Shook David, Chief Medical Officer

Sold 500 shares ($6.35K)

10 Sep 2026 Form 4: Aguirre Jarrad Mattieu, Chief Medical Officer

Granted 47,500 Option (right to buy)

10 Sep 2026 Form 3: Aguirre Jarrad Mattieu, Chief Medical Officer

Holds 20,279 shares of Common Stock

10 Sep 2026 8-K: Other Events

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

25 Aug 2026 Form 4: Seely Lynn, Director

Sold 9,589 shares ($149K)

25 Aug 2026 Form 4: Hill Stephen J., Chief Operating Officer

Sold 989 shares ($15.4K)

25 Aug 2026 Form 4: Lee Gary K., Chief Scientific Officer

Sold 1,457 shares ($22.6K)

14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support